AUB ScholarWorks

Oxcarbazepine in painful diabetic neuropathy: Results of a dose-ranging study

Show simple item record Beydoun A. Shaibani A. Hopwood M. Wan Y.
dc.contributor.editor Jun-2006 2017-10-05T15:38:53Z 2017-10-05T15:38:53Z 2006
dc.identifier 10.1111/j.1600-0404.2006.00631.x
dc.identifier.issn 00016314
dc.description.abstract Objectives - To evaluate the efficacy and safety of oxcarbazepine in patients with diabetic neuropathy in a multicenter, double-blind, placebo-controlled, dose-ranging 16-week study. Methods - A total of 347 patients were randomized to oxcarbazepine 600 mg-day (n = 83), 1,200 mg-day (n = 87), 1,800 mg-day (n = 88), or placebo (n = 89). The primary efficacy variable was change in mean visual analog scale (VAS) score from baseline to the last week of the study. Results - No difference between any oxcarbazepine group and the placebo group was noted for the primary efficacy variable. Both the 1,200- and 1,800-mg-day groups showed a trend toward statistical significance (P = 0.101, P = 0.096, respectively). Statistically significant differences were found between the oxcarbazepine 1,200-mg-day (P = 0.038) and 1,800-mg-day (P = 0.005) groups and placebo in the overall mean weekly VAS scores for the entire double-blind treatment phase. Conclusions - Although the primary efficacy variable did not reach statistical significance, patients taking oxcarbazepine 1,200 and 1,800 mg-day showed improvements in VAS scores compared with placebo. Oxcarbazepine may provide clinically meaningful pain relief in patients with painful diabetic neuropathy. © 2006 The Authors.
dc.format.extent Pages: (395-404)
dc.language English
dc.publisher OXFORD
dc.relation.ispartof Publication Name: Acta Neurologica Scandinavica; Publication Year: 2006; Volume: 113; no. 6; Pages: (395-404);
dc.source Scopus
dc.title Oxcarbazepine in painful diabetic neuropathy: Results of a dose-ranging study
dc.type Article
dc.contributor.affiliation Beydoun, A., American University of Beirut, Beirut, Lebanon, American University of Beirut, P.O. Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon
dc.contributor.affiliation Shaibani, A., St. Lukes Medical Tower, Houston, TX, United States
dc.contributor.affiliation Hopwood, M., Clinical Research and Development, Novartis Pharmaceuticals Inc., East Hanover, NJ, United States
dc.contributor.affiliation Wan, Y., Biostatistics and Statistical Reporting, Novartis Pharmaceuticals Inc., East Hanover, NJ, United States
dc.contributor.authorAddress Beydoun, A.; American University of Beirut, P.O. Box 11-0236, Riad El Solh 1107 2020, Beirut, Lebanon; email:
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Neurology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Neurology
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Beydoun, A
dc.contributor.authorInitials Shaibani, A
dc.contributor.authorInitials Hopwood, M
dc.contributor.authorInitials Wan, Y
dc.contributor.authorReprintAddress Beydoun, A (reprint author), Amer Univ Beirut, POB 11-0236, Beirut, Lebanon.
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Backonja M, 2003, CLIN THER, V25, P81, DOI 10.1016-S0149-2918(03)90011-7; Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001-jama.280.21.1831; Bang Lynne, 2003, Paediatr Drugs, V5, P557, DOI 10.2165-00148581-200305080-00006; Barcs G, 2000, EPILEPSIA, V41, P1597; Beydoun A, 2000, NEUROLOGY, V54, P2245; Beydoun A, 2001, EPILEPSY BEHAV, V2, P187, DOI 10.1006-ebeh.2001.0198; BEYDOUN A, 2002, J PAIN S1, V3, P38; Beydoun A, 2004, CLIN J PAIN, V20, P174, DOI 10.1097-00002508-200405000-00007; Bill PA, 1997, EPILEPSY RES, V27, P195, DOI 10.1016-S0920-1211(97)00024-7; Christe W, 1997, EPILEPSY RES, V26, P451, DOI 10.1016-S0920-1211(96)01013-3; Collins SL, 2000, J PAIN SYMPTOM MANAG, V20, P449, DOI 10.1016-S0885-3924(00)00218-9; DAM M, 1989, EPILEPSY RES, V3, P70; Dogra S, 2005, EUR J PAIN, V9, P543, DOI 10.1016-j.ejpain.2004.11.006; Duby JJ, 2004, AM J HEALTH-SYST PH, V61, P160; Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001-archneur.60.11.1524; Farrar JT, 2003, J PAIN SYMPTOM MANAG, V25, P406, DOI 10.1016-S0885-3924(03)00162-3; Glauser TA, 2000, NEUROLOGY, V54, P2237; GROSSKOPF J, IN PRESS ACTA NEUROL; Guerreiro MM, 1997, EPILEPSY RES, V27, P205, DOI 10.1016-S0920-1211(97)00025-9; Ichikawa K, 2001, EUR J PHARMACOL, V420, P119, DOI 10.1016-S0014-2999(01)01007-X; Lindstrom P., 1987, PAIN S, V30, pS85; MCQUAY H, 1995, BRIT MED J, V311, P1047; Raskin P, 2004, NEUROLOGY, V63, P865; Rosenstock J, 2004, PAIN, V110, P628, DOI 10.1016-j.pain.2004.05.001; Sachdeo R, 2001, NEUROLOGY, V57, P864; Schachtar SC, 1999, NEUROLOGY, V53, P2211; Schmader KE, 2002, CLIN J PAIN, V18, P350, DOI 10.1097-00002508-200211000-00002; STEFANI A, 1995, EPILEPSIA, V36, P997, DOI 10.1111-j.1528-1157.1995.tb00958.x; Thienel U, 2004, ACTA NEUROL SCAND, V110, P221, DOI 10.1111-j.1600-0404.2004.00338.x; WAMIL A W, 1991, Epilepsia, V32, P65; Wellington K, 2001, CNS DRUGS, V15, P137, DOI 10.2165-00023210-200115020-00005
dc.description.citedCount 59
dc.description.citedTotWOSCount 53
dc.description.citedWOSCount 52
dc.format.extentCount 10
dc.identifier.coden ANRSA
dc.identifier.pubmedID 16674606
dc.identifier.scopusID 33745911608
dc.publisher.address 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
dc.relation.ispartOfISOAbbr Acta Neurol. Scand.
dc.relation.ispartOfIssue 6
dc.relation.ispartofPubTitle Acta Neurologica Scandinavica
dc.relation.ispartofPubTitleAbbr Acta Neurol. Scand.
dc.relation.ispartOfVolume 113
dc.source.ID WOS:000237349700005
dc.type.publication Journal
dc.subject.otherAuthKeyword Antiepileptic drug
dc.subject.otherAuthKeyword Diabetic neuropathy
dc.subject.otherAuthKeyword Neuropathic pain
dc.subject.otherAuthKeyword Oxcarbazepine
dc.subject.otherAuthKeyword Randomized study
dc.subject.otherChemCAS oxcarbazepine, 28721-07-5
dc.subject.otherChemCAS paracetamol, 103-90-2
dc.subject.otherChemCAS Analgesics
dc.subject.otherChemCAS Anticonvulsants
dc.subject.otherChemCAS Carbamazepine, 298-46-4
dc.subject.otherChemCAS oxcarbazepine, 28721-07-5
dc.subject.otherIndex benzodiazepine derivative
dc.subject.otherIndex oxcarbazepine
dc.subject.otherIndex paracetamol
dc.subject.otherIndex placebo
dc.subject.otherIndex serotonin uptake inhibitor
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex article
dc.subject.otherIndex ataxia
dc.subject.otherIndex clinical trial
dc.subject.otherIndex confusion
dc.subject.otherIndex constipation
dc.subject.otherIndex controlled clinical trial
dc.subject.otherIndex controlled study
dc.subject.otherIndex diabetic neuropathy
dc.subject.otherIndex diarrhea
dc.subject.otherIndex dizziness
dc.subject.otherIndex double blind procedure
dc.subject.otherIndex drug dose reduction
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug megadose
dc.subject.otherIndex drug safety
dc.subject.otherIndex drug tolerability
dc.subject.otherIndex dysarthria
dc.subject.otherIndex fatigue
dc.subject.otherIndex female
dc.subject.otherIndex headache
dc.subject.otherIndex human
dc.subject.otherIndex hyponatremia
dc.subject.otherIndex major clinical study
dc.subject.otherIndex male
dc.subject.otherIndex maximum permissible dose
dc.subject.otherIndex multicenter study
dc.subject.otherIndex nausea
dc.subject.otherIndex neuropathic pain
dc.subject.otherIndex quality of life
dc.subject.otherIndex randomized controlled trial
dc.subject.otherIndex scoring system
dc.subject.otherIndex somnolence
dc.subject.otherIndex statistical significance
dc.subject.otherIndex tremor
dc.subject.otherIndex visual analog scale
dc.subject.otherIndex vomiting
dc.subject.otherIndex Adult
dc.subject.otherIndex Aged
dc.subject.otherIndex Analgesics
dc.subject.otherIndex Anticonvulsants
dc.subject.otherIndex Carbamazepine
dc.subject.otherIndex Diabetic Neuropathies
dc.subject.otherIndex Dizziness
dc.subject.otherIndex Dose-Response Relationship, Drug
dc.subject.otherIndex Double-Blind Method
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Male
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Nausea
dc.subject.otherIndex Pain
dc.subject.otherIndex Pain Measurement
dc.subject.otherIndex Patient Compliance
dc.subject.otherIndex Placebo Effect
dc.subject.otherIndex Treatment Outcome
dc.subject.otherKeywordPlus CONTROLLED CLINICAL-TRIAL
dc.subject.otherKeywordPlus DOUBLE-BLIND
dc.subject.otherKeywordPlus POSTHERPETIC NEURALGIA
dc.subject.otherKeywordPlus PARTIAL SEIZURES
dc.subject.otherKeywordPlus PLACEBO
dc.subject.otherKeywordPlus MONOTHERAPY
dc.subject.otherKeywordPlus GABAPENTIN
dc.subject.otherKeywordPlus MANAGEMENT
dc.subject.otherKeywordPlus PHENYTOIN
dc.subject.otherWOS Clinical Neurology

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


My Account